Impact of TP53 Mutations on Survival in Large B-Cell Lymphoma Patients Treated with CAR-T

195 adult patients with relapsed/refractory large B-cell lymphoma were analyzed for TP53 mutations and survival outcomes. The dataset, created by Rui Liu and last updated in June 2026, compares 151 patients receiving CD19-directed CAR-T cell therapy against 44 receiving non-CAR-T chemotherapy-based treatments. It includes metrics like objective response rates and median overall survival stratified by mutation status and treatment.

Use Cases

• Compare survival outcomes between CAR-T and chemotherapy treatments based on TP53 mutation status.
• Analyze the association between TP53 mutation type (e.g., missense vs. disruptive) and treatment response.
• Investigate the impact of mutation protein domain (DNA-binding vs. non-DNA-binding) on patient survival.
• Model the prognostic risk of TP53 mutations in the context of modern lymphoma therapies.

Strengths

• Includes specific patient counts: 195 total, 75 with TP53 mutations, and 151 treated with CAR-T therapy.
• Reports concrete clinical outcomes, such as median overall survival of 12.13 months for mutated patients on CAR-T vs. 2.20 months on chemotherapy.
• Evaluates mutational architecture, including mutation type and protein domain, within the TP53-mutant cohort.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single retrospective study of 195 patients, which may limit generalizability.

Provenance

Source

figshare, author Rui Liu.

Collection Method

Retrospective analysis of 195 adult patients with r/r LBCL who underwent Next-Generation Sequencing (NGS).

Freshness

Last updated 2026-06-03 06:06:56; freshness should be verified.